Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

Conditions: Multiple Myeloma in Relapse
Multiple Myeloma

First Posted Date: 2016-01-28

Last Posted Date: 2017-08-28

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT02666209

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide (Control)
Drug: Lenalidomide
Drug: Carfilzomib
Drug: Dexamethasone

First Posted Date: 2016-01-20

Last Posted Date: 2024-08-15

Lead Sponsor: University of Chicago

Target Recruit Count: 180

Registration Number: NCT02659293

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Wayne State University - Karmanos Cacner Institute, Detroit, Michigan, United States
🇵🇱
Polish Myeloma Consortium, Poznań, Poland

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Lenalidomide
Other: autologous PBMC reconstitution
Other: ASCT

First Posted Date: 2016-01-14

Last Posted Date: 2017-08-18

Lead Sponsor: Hearn Jay Cho

Target Recruit Count: 15

Registration Number: NCT02655458

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib

Phase 2

Completed

Conditions: Diffuse Large B-Cell Lymphoma Unclassifiable

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Ibrutinib
Drug: Lenalidomide
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2015-12-21

Last Posted Date: 2024-03-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT02636322

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Mantle Cell Lymphoma
Untreated

Interventions: Drug: Lenalidomide
Drug: R-CHOP
Drug: high-dose cytarabine (HIDAC)

First Posted Date: 2015-12-17

Last Posted Date: 2023-11-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 49

Registration Number: NCT02633137

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Follicular

Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ]
Drug: Lenalidomide
Drug: Obinutuzumab

First Posted Date: 2015-12-16

Last Posted Date: 2022-04-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 38

Registration Number: NCT02631577

Locations: 🇺🇸
University Miami, Miami, Florida, United States
🇫🇷
Hopital du Bocage, Dijon, France
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 13 locations

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Transformed Non-Hodgkin Lymphoma
Recurrent Transformed Non-Hodgkin Lymphoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Biological: Rituximab

First Posted Date: 2015-12-11

Last Posted Date: 2024-07-01

Lead Sponsor: Academic and Community Cancer Research United

Target Recruit Count: 30

Registration Number: NCT02628405

Locations: 🇺🇸
Carle Cancer Center NCI Community Oncology Research Program, Urbana, Illinois, United States
🇺🇸
Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States
🇺🇸
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States

and more 9 locations

Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Plasma Cell Myeloma
Transplant-Related Carcinoma

Interventions: Drug: Ixazomib Citrate
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide

First Posted Date: 2015-12-02

Last Posted Date: 2024-04-25

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT02619682

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Laser Peripheral Iridotomy Plus Laser Peripheral Iridoplasty for Primary Angle Closure

Not Applicable

Conditions: Glaucoma, Angle-Closure

Interventions: Drug: Pilocarpine
Procedure: LPIP plus LPI
Drug: Proparacaine
Procedure: LPI

First Posted Date: 2015-11-24

Last Posted Date: 2018-09-06

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 240

Registration Number: NCT02613013

Locations: 🇨🇳
Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China

Comparison of In-the-bag Stability Between Single-piece and Three-piece Intraocular Lens

Not Applicable

Completed

Conditions: Cataract

Interventions: Procedure: Phacomulsification lens removal cataract surgery with three-piece Intraocular lens(IOL) implantation
Procedure: Phacomulsification lens removal cataract surgery with single-piece Intraocular lens(IOL) implantation
Drug: Subconjunctival dexamethasone
Device: Viscoelastic materials
Drug: proparacaine

First Posted Date: 2015-11-20

Last Posted Date: 2015-11-20

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 65

Registration Number: NCT02609997

Locations: 🇨🇳
Zhognshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy